Skip to main content
main-content

01.12.2017 | Research | Ausgabe 1/2017 Open Access

Virology Journal 1/2017

Identification of a novel linear B-cell epitope using a monoclonal antibody against the carboxy terminus of the canine distemper virus nucleoprotein and sequence analysis of the identified epitope in different CDV isolates

Zeitschrift:
Virology Journal > Ausgabe 1/2017
Autoren:
Li Yi, Zhigang Cao, Mingwei Tong, Yuening Cheng, Yong Yang, Shuang Li, Jianke Wang, Peng Lin, Yaru Sun, Miao Zhang, Shipeng Cheng

Background

Canine distemper virus (CDV) is an enveloped negative-strand RNA virus classified into the genus Morbillivirus within the family Paramyxoviridae [1]. CDV infection results in systemic disease with involvement of the central nervous system and the respiratory and gastrointestinal tracts [2]. With the rapidly development of fur-animal industry and the expansion number of dogs and fur animals, the economic loss is significant due to CDV infection, especially in mink and fox farms in China [3]. Canine distemper (CD) disease has raised global attention with its extensively spreading.
Nucleoprotein (NP) is the most abundant and highly immunogenic protein in Morbillivirus, and is an internal protein which packs the viral RNA genome and forms a helical nucleocapsid. It can be used as the basis of most diagnostic assays for CDV presently [4]. The interest in diagnostic applications of CDV NP has focused attention on identifying more antigenic epitopes, especially B cell epitopes [5]. However, the data on B cell epitopes of nucleoprotein are still limited, especially in the C-terminal region (aa 401–523).The objective of this study was to identify B cell epitopes in CDVNP C-terminal region using monoclonal antibodies. Additionally, the high degree of variation in NP C-terminal region can be used to classify CDV into different genotypes [6]. The epitope identified in this area may be diverse and may be used as a tag to distinguish different CDV isolates. Therefore, we decided to perform the specific mAbs and identify their epitopes in CDVNP C-terminal region precisely.
In this study, we generated one CDV NP-reactive mAb and mapped its linear B-cell epitope. We also used bioinformatics tools to locate linear B-cell epitope within the CDV NP C-terminal region (aa 401–523) to a predicted 3-dimensional (3D) model. These results will facilitate the development of epitope-based preventive and diagnostic strategies for CDV infection and provide resources for better understanding the antigenic structure and function of the CDV NP protein.

Methods

Ethics statement

The protocol of this study was carried out in accordance with guidelines of animal welfare of World Organization for Animal Health. All experimental protocols were approved by the Review Board Institute of Special Animal and Plant Sciences, Chinese Academy of Agricultural Sciences (CAAS).

Cell lines and viruses

Vero and the SP2/0 myeloma cell line were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Invitrogen) in a humidified incubator with 5% CO2 at 37 °C. media for Vero cells and SP2/0 myeloma cells were supplemented with 10 and 20% heated-inactivated fetal bovine serum (GIBCO, Invitrogen) along with antibiotics (0.1 mg/ml of streptomycin and 100 IU/ml of penicillin), respectively. The CDV-PS [7] strain (JN896331.1) was lab-adapted and was propagated in Vero cells using standard techniques.

Cloning of the CDV NP C-terminal region (aa 401–523) and prokaryotic expression of recombinant protein

Vero cells were infected with the lab-adapted CDV-PS strain. At 40–50% cytopathic effect, the cells were lysed and total RNA was extracted by using an RNeasy RNA extraction kit (Qiagen) according to the manufacturer’s instructions. Following RNA extraction, cDNA was synthesized by reverse transcription using a First Strand cDNA synthesis kit and random primers (Roche Inc., Germany). This cDNA was used to amplify the C-terminal region (aa 401–523) of the N gene by using the forward and reverse primers CDV N-KpnI-aa401 (5′-CCGGATCCGGTGCAGTTGCAC-3′) and CDV N-SacI-aa523 (5′-GCGAGCTCACCTTCGGTAA-3′). The PCR product was cloned into the pET32a(+) expression vector (Novagen, USA) by double digestion with KpnI and SacI. Plasmid construction was verified by restriction enzyme digestion, PCR, and DNA sequencing. The recombinant plasmid, named pET-N-c, was transformed to E. coli to produce recombinant protein fused with a six-histidine tag. Recombinant protein was induced by adding isopropyl-D-thiogalactopyranoside (IPTG). For expression, IPTG was added to a final concentration of 0.75 mM and cells were incubated for 6 h at 37 °C. Production of recombinant protein was evaluated by sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The recombinant protein was purified by affinity chromatography using a His-Tag resin according to manufacturer’s instruction (Roche Inc., Germany). Production of the purified recombinant protein was confirmed by Western Blot using CDV-positive dog serum as follows. Recombinant protein was boiled 5–10 min, separated by SDS-PAGE, and transferred to nitrocellulose membranes. The membranes were blocked with 5% skim milk overnight at 4 °C to reduce non-specific binding. The membrane was incubated with CDV-positive dog serum as the primary antibody at a 1:100 dilution. After incubation, each was washed five times with PBST, and then it was treated with HRP-conjugated rabbit anti-dog secondary antibodies (Bioss Inc., China). The color was developed using 3,3′-diaminobenzidine tetrahydrochloride (DAB) and stopped by rinsing in deionized water followed by drying the membrane.

Preparation and identification of mAb against CDV recombinant N protein (401-523aa)

The truncated N protein (401-523aa) was used as an antigen to immunize mice to generate CDV N-specific mAbs according to standard procedures [8]. Six-week-old female BALB/c mice were immunized subcutaneously with 100 μg recombinant protein as above. After 14 days, mice received a subcutaneous booster immunization consisting of 200 μg purified protein. The mice received a final booster immunization 3 days prior to harvesting splenocytes for hybridoma generation. Splenocytes were fused with SP2/0 myeloma cells at a ratio of 4:1 using polyethylene glycol (PEG4000, Sigma-Aldrich). The cells were seeded into 96-well plates in HAT medium (DMEM containing 20% FBS, 0.1 mg/ml streptomycin, 100 IU/ml penicillin, 100 mM hypoxanthine, 16 mM thymidine, and 400 mM aminopterin) for 6 days at which time the media was replaced with HT medium (HAT medium is lacking aminopterin). After HAT/HT selection, culture supernatants of surviving clones were screened for reactivity and specificity by indirect ELISA, WB and IFA.
For WB, the MAb was analyzed by western blotting with Vero cells that had been infected with CDV-PS. Each sample was separated by 12% SDS-PAGE, and transferred onto nitrocellulose membranes with a Transblot apparatus (Bio-Rad, USA). The membrane was incubated individually with the appropriate dilution of the mAbs, and then incubated with a 1:4000 HRP-conjugated rabbit anti-mouse antibody. Immunoreactive bands were visualized using DAB Western Blotting Detection Reagents (CWBIO, China).
For IFA, the 96 well microtiter plate, where Vero cells were cultured, was added with CDV (CDV-PS strain). About 24-48 h later, Vero cells were fixed with 90% (V/V) ethylalcohol in pre-cooled distilled water at 4 °C for 30 min. The cells were washed with phosphate buffered saline (PBS, pH 7.4) with 0.1% Tween-20 (Sigma, USA) and were added in hybridoma supernatants for incubating at 37 °C for 1 h. After the plates were washed again, a FITC-conjugated goat anti-mouse IgG (Sigma, USA) was added as secondary antibody. Finally, the plate was viewed by a fluorescence microscope after washing three times.
The mAb subtypes was determined using the Mouse Monoclonal-Ab-ID kit (Invitrogen, CA, USA) as the manufacturer’s instructions.

Identification of the linear epitope by Pepscan analysis

Twenty-three overlapping synthetic peptides (15aa) corresponding to the coding sequence of recombinant N protein (aa 401–523) were synthesized (Sangon, China) to map the mab binding epitope. The synthetically peptides were 15 amino acid (aa) residues long and each peptide overlapped the previous peptide sequence by 10 aa residues. Peptides plated as coating antigen to assess the mAb binding by Pepscan analysis. Briefly, the ELISA plates were coated with these peptides at 100 ng well−1 at 4 °C overnight and then incubated with the culture supernatant of hybridoma cells at 37 °C for 1 h. HRP-conjugated goat anti-mouse IgG was used as the secondary antibodies at a 1:4000 dilution at 37 °C for 1 h, followed by color development with substrate solution containing TMB. Based on the result of this initial screen used to identify a linear region of N protein (401-523aa) recognized by the mAb, we designed and synthesized a series of progressively truncated polypeptides to perform a more refined mapping of the minimal linear peptide epitope recognized by the mAb using the ELISA approach described above.

Location analysis of identified epitope in the CDV N protein (401-523aa)

In order to locate and explain the general spatial relationship of epitope on CDV N protein (401-523aa) according to the homology modeling from PDB, a 3D model of the protein was generated by using I-TASSER online sever [9, 10]. And the PyMol software was used based on the results of I-TASSER online sever to analyze the epitope locations onto N protein 3D model (401-523aa).

Homology analysis of defined epitope

To investigate the homology of the epitope to equivalent CDV sequences, alignments of sequences from homologous regions of 17 CDV strains (including CDV Asia-1, Vaccine and America-2 genotype strains) were completed by using the DNASTAR Lasergene program (Windows version; DNASTAR Inc., Madison, WI).

Phylogenetic analysis of the N gene C-terminal region (aa 401–523) from 19 chinese clinical Canine distemper virus strains

Alignment analysis was also performed between the 19 Chinese CDV clinical isolates, the factors of isolation time and geographical location of Chinese clinical strains were considered (Table 1).
Table 1
Characteristics of canine distemper virus in domestic dogs in this study
Strain
Region
Host
Origin
Year
Accession no.
Clinical symptoms
CDV-WH-13
Wuhan
Dog
Nasal swab
2015
KU558767
Coughing, eye discharge
CDV-WH-30
Wuhan
Dog
Nasal swab
2015
KU558768
Eye discharge
CDV-WH-31
Wuhan
Dog
Nasal swab
2015
KU558769
Nasal discharge, vomiting
CDV-WH-33
Wuhan
Dog
Nasal swab
2015
KU558770
Nervous signs
CDV-WH-34
Wuhan
Dog
urine
2015
KU558771
Nasal discharge
CDV-WH-43
Wuhan
Dog
urine
2015
KU558772
Vomiting, diarrhea
CDV-WH-46
Wuhan
Dog
fecal
2015
KU558773
Eye discharge
CDV-WH-56
Wuhan
Dog
fecal
2015
KU558774
Diarrhea
CDV-WH-60
Wuhan
Dog
Nasal swab
2015
KU558775
Nervous signs
CDV-WH-64
Wuhan
Dog
blood
2015
KU558776
Nasal discharge
CDV-WH-72
Wuhan
Dog
Nasal swab
2015
KU558777
Diarrhea
CDV-SH-3
Shanghai
Dog
blood
2016
KU558778
Nasal discharge
CDV-SH-7
Shanghai
Dog
Nasal swab
2015
KU558779
Diarrhea
CDV-CC-4
Changchun
Dog
Nasal swab
2016
KU558780
Nasal discharge
CDV-CC-11
Changchun
Dog
Nasal swab
2015
KU558781
Nervous signs
CDV-CC16
Changchun
Dog
Nasal swab
2015
KU558782
Diarrhea
CDV-CC-27
Changchun
Dog
Nasal swab
2015
KU558783
Nasal discharge
CDV-DL-3
Dalian
Dog
Nasal swab
2016
KU558784
Nasal discharge
CDV-DL-5
Dalian
Dog
Nasal swab
2015
KU558785
Vomiting, diarrhea
RNA was extracted from Vero cells infected with wildtype CDV Chinese strains. The extraction was done as indicated above. The first-strand cDNAs were synthesized using random primers. For each virus, the coding sequence of the C-terminal region (aa 401–523) was amplified by RT-PCR using forward and reverse primers as indicated above. To assess the status of relationship among representative clinical CDV viruses, we built a CDV phylogenetic tree of nucleocapsid protein genes which contains the identified CDV N linear epitope. The C-terminal part of the nucleocapsid protein genes from the 19 sampled dogs were assembled and edited over a total length of 372 bp using the SeqMan program (Lasergene7.1, DNASTAR Inc., Madison, WI).Subsequently, these sequence data were submitted to GenBank, and the accession numbers are shown in Table 1. For comparative analysis, the nucleotide sequences of 13 CDV strains available from GenBank, including the 19 sequences characterized here, were aligned using the Clustal W program of MEGA 5 software, and a phylogenic tree was constructed using the neighbor-joining (NJ) method. The robustness of the phylogenetic analysis was assessed by a bootstrap analysis with 1000 replicates.

Results

Prokaryotic expression and purification of recombinant N protein (C-terminal 401-523aa)

The recombinant N protein (C-terminal 401-523aa) fused with a six-histidine tag was successfully expressed in Escherichia coli BL21 (DE3). The recombinant protein was predominantly found within the soluble fraction of the induced E. coli after ultra-sonication (Fig. 1a) and was subsequently purified by amylose resin affinity chromatography (Fig. 1b). The recombinant protein was recognized by CDV-positive dog serum in Western blot (Fig. 1c). The expected size of the expressed recombinant protein was about 35 kD for 123 amino acids in NP protein (about 15kD) and expression vector tag (about 20 kD). And the approximate size of the expressed protein was as the same as the expected size.

Preparation and identification of mAb against CDV N protein

We immunized BALB/c mice with purified the recombinant protein to generate hybridoma lines secreting antibodies against the CDV N protein. Hybridoma cell supernatants were screened by indirect enzyme-linked immunosorbent assay (ELISA) and selected hybridoma lines were subcloned by limiting dilution (data not shown). One hybridoma line stably producing antibodies against CDV N protein were obtained and named C8.
Western blot analysis revealed that mAb produced by hybridoma line reacted with the native N protein derived from CDV3-infected Vero cells, but did not recognize uninfected Vero cell lysates (Fig. 2a). In addition, the mAb was able to react with Vero cells infected with CDV3 (Fig. 2b) by indirect immune-fluorescence assay (IFA), but did not bind appreciably to uninfected Vero cells (Fig. 2c).

Identification of B-cell epitope recognized by CDV carboxy terminus of N protein mAb

We next sought to define the linear epitopes within the CDV N protein (C-terminal 401-523aa) recognized by the mAb. Peptide scanning technology was used to prepare a group of 23 overlapping synthetic peptides (15 amino acids [aa]) corresponding to the truncated N protein (C-terminal 401-523aa). Each 15 aa synthetic peptide overlapped the previous peptide sequence by 10 aa residues. The synthetic peptides were respectively used as coating antigen in an indirect ELISA to identify the epitope recognized by the C8 mAb. The C8 mAb recognized both synthetic peptides 440ENQGGDKYPIHFNDE454 and 445DKYPIHFNDERFPGY459 (Fig. 3a), suggesting that the core linear epitope might be represented by the sequence 445DKYPIHFNDE454which was the overlapping N protein sequence present in both peptides. To define the minimal linear peptide epitope required for mAb recognition, we designed and synthesized a series of progressively truncated polypeptides starting with the initial peptides recognized by the mAb as described above. Amino acids were progressively deleted from the C- or N-terminus of the two peptide sequences (445DKYPIHFNDERF456and 442QGGDKYPIHFNDE454) respectively. The minimal peptide epitope recognized by mAb C8 was 444GDKYPIHFNDER455 (Fig. 3b).

Location analysis of B cell identified epitope in the CDV N protein (C-terminal 401-523aa)

Because the 3D structure of CDV N protein (C-terminal 401-523aa) was not available in Protein Data Bank (PDB), several 3D homology modeling about it was obtained from I-TASSER online sever. Then we had chosen one of them according to high confidence that corresponding with the information of secondary structure of N protein (C-terminal 401-523aa).The locations of identified epitope was showed in the context of the deduced 3D protein model (Fig. 4).

Alignment and conversation analysis of the defined epitope

We next analyzed the level of conservation of the defined epitope among different CDV genotypes.We aligned sequences corresponding to the region encompassing the mAb C8 epitope (aa 444–455) from the CDV isolates for which sequence information was available from the NCBI protein database (http://​www.​ncbi.​nlm.​nih.​gov/​protein).Alignment of the amino acid sequences revealed that the peptide epitope recognized by mAb 1 N8 is not conserved among CDV isolates, which has several substitutions in genotype Asia-1, Vaccine and America-2 strains (Table 2).The CDV genotypeAmerica-2 and Vaccine strains (Onderstepoort and Vaccine Hungary) displayed a single N➔S substitution at amino acid position 452. The other CDV Vaccine strains (Lederle and CDV3) displayed K➔R and N➔S substitutions at amino acid position 446 and 452. K446R and N452S substitutions were always observed in the genotype Asia-1 strains, while the Y447S, P448S and F451L/I/V substitutions were also observed.
Table 2
Conservation analysis of the epitope C8 among different CDV strain
https://static-content.springer.com/image/art%3A10.1186%2Fs12985-017-0858-6/MediaObjects/12985_2017_858_Tab2_HTML.gif
The yellow highlight indicated the amino acid identity and differences among different CDV strains

The defined epitope alignment between Chinese CDV clinical isolates

To assess the degree of conservation of the linear epitope in Chinese clinical isolates, we analyzed the CDV N protein (C-terminal 401-523aa) sequences from Chinese isolates in domestic dogs during 2015–2016.Analysis of these sequences from 19CDVclinical isolates indicated that the C8 epitope,444GDKYPIHFNDER455 is highly conserved among CDV Chinese strains.Limited amino acid mutations were present in three CDV strains, whereas an F➔L substitution at position 451 was noted in CDV-WH-30, CDV-WH-43 and an P➔S substitution at position 448 was noted in CDV-CC-11 (Fig. 5).

Phylogenetic analysis of CDV C-terminal part of the nucleocapsid protein gene

Phylogenetic analysis showed that the 19 CDV strains were separated into two groups. The strains WH-13, WH-33, WH-31, WH-56, WH-60, DL-5, SH-3 and SH-7 displayed high sequence identity to each other and were grouped in one clade along with some CDV strains from China such as CDV-PS (JN896331). The other strains WH-30, WH-43, CC-11, DL-3, CC-16, CC-27 and CC-4, formed another single branch sharinghigh nucleotide sequence identity with Chinese strain ZJ-7 (JF343964) which is a high virulent strain. The strains WH-30 and WH-43, including one substitution with F451L in the identified epitope, had a close evolutionary relationship tostrain ZJ-7 (JF343964).The strain CC-11, with one substitutionP448S in the epitope, shared a higher variation and formed in a single branchindividually, which seems like the ancestor of strains SD(14)7 and LN(10)1 (Fig. 6).

Discussion

The Morbillivirus nucleoprotein is an important structural protein playing the role of virus assembly and has some regulatory functions in viral transcription and replication [11].
Recent structural studies on NP within the genus Morbillivirus have revealed that it consists of three regions: the highly conserved central region, the poorly conserved N- and C-terminal domain. The N-terminal region, with conserved sequences required for self-assembly and RNA binding; and a C-terminal region, which is intrinsicallydisordered and protrudes from the viral nucleocapsid surface [12, 13]. Regions of binding with P protein in CDV have recently been mapped within the NP C-terminal region, in agreement with the accessibility of C-terminal region on the surface of the nucleocapsid [14]. Localization of B cell epitopes may provide additional information on the structure of CDV NP C-terminal region. A detailed analysis of the antibody epitope within this area would further our understanding of CDV immunity and the development of epitope-based marker vaccines and diagnostic tools.
Moreover, this is the first report of an epitope (444GDKYPIHFNDER455) in the CDV NP C-terminal region, which can be potentially valuable for further CDV research.
In this study, we used prokaryotic recombinant protein HIS-NP(C-terminal) for the immunization of BALB/c mice and screening hybridoma supernatants for NP-reactive antibody production to exclude potential false positive results. One CDV NP-reactive mAb that recognized NP protein produced by CDV-PS strain was generated.
We screened a panel of CDV N protein (C-terminal 401-523aa) overlapping synthetic peptidesto map mAb reactivity to initial B cell linear epitope. And the progressively truncated peptides were synthesized to define the minimal B cell linear epitope recognized by the mAb. In the initial screen, mAb C8 reacted with twosynthetic peptides which overlapped by 10 amino acids. The binding of C8 to peptide 440ENQGGDKYPIHFNDE454 resulted in a twice higher OD450 value when compared to C8 binding to 445DKYPIHFNDERFPGY459, suggesting that the overlapping sequence was sufficient for C8 binding, but additional residues present in 445DKYPIHFNDERFPGY459 enhanced binding. A peptide lacking the C-terminal 444G residue of this core peptide sequence displayed a strong reduction in C8 binding. When residues at the C-terminus were progressively added, no more increment in C8 binding was noted until the residue 455R was added. Therefore, we demonstrated that 444G and 455R were critical components of the linear epitope.
Based on previous research [15], the NP C-terminal region appears to be a tail extending from the surface of the globularbody. We also mapped the location of identified epitope on 3D homology model of NP protein C-terminal region in this study. There is no C-terminal ends of the NP protein crystal structure available now, so the I-TASSER online sever was used to predict the 3D structure based on different templates of high confidence by sending the primary sequence of NP protein (401-523aa). In this accord, the B-cell epitope recognized by the mAb is predicted to be located at the surface of the protein within a kind of helix structure.The analysis of the protein structure could potentially facilitate the function study of the NP C-terminal protein.
Alignment of NP amino acid sequences of different CDV genotypes and CDV clinical isolates in China showed that the defined antibody epitope isless conserved among CDV genotypes, which has several substitutions in genotype Asia-1, Vaccine and America-2 strains. The N452S substitution is a solid change in CDV genotype America-2 and Vaccine (America-1).There are another substitutions in this defined epitope, which demonstrates less conserved between different CDV strains. To assess the degree of conservation of the linear epitope, we analyzed these sequences from Chinese isolates in domestic dogs during 2015–2016. Three out 19 (15.7%) amino acid mutations were present in Chinese CDV strains, which are F451L and P448S. Interestingly, the F451L substitution also can be observed in the strain ZJ7 isolate [16] (JF343964) which is a high virulent strain. Moreover, the two isolates with F451L substitutionformed a single branch sharing high identity with Chinese strain ZJ-7 in the phylogenetic tree based on C-terminal part of the nucleocapsid protein genes, so the F451L substitution in CDV NP protein maybe a tag which can identified as a high virulent strain. On the other hand, the CDV NM strain, CDV-ZC and XJ-4 [17] stain show some substitutions in this identified epitope, while the hosts of viral infection are fox, raccoon dog and Tibetan mastiff, respectively. There may be a relationship between host range and this epitope.

Conclusions

The identification of less conserved epitope within the NP protein (401-523aa) of CDV could provide important insights into the structure and function of the NP protein. Moreover, the defined epitope can be used to design suitable serological methods for epidemiological surveillance, and may suggest potential targets for pharmacological inhibitors. The established MAb and defined epitope could be used to further study the structure and function of NP protein during CDV infection and provide a foundation for the development of novel epitope-based vaccines.

Acknowledgements

Not applicable.

Funding

This study was supported by the Jilin Province Research Funds (20150101104JC) and (20150201006NY).

Availability of data and materials

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

Ethics approval

The protocol of the study was carried out in accordance with guidelines of animal welfare of World Organization for Animal Health. All experimental protocols were approved by the Review Board Institute of Special Animal and Plant Sciences, Chinese Academy of Agricultural Sciences (CAAS).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

Virology Journal 1/2017 Zur Ausgabe


 

Neu im Fachgebiet Innere Medizin

Meistgelesene Bücher aus der Inneren Medizin

2017 | Buch

Rheumatologie aus der Praxis

Entzündliche Gelenkerkrankungen – mit Fallbeispielen

Dieses Fachbuch macht mit den wichtigsten chronisch entzündlichen Gelenk- und Wirbelsäulenerkrankungen vertraut. Anhand von über 40 instruktiven Fallbeispielen werden anschaulich diagnostisches Vorgehen, therapeutisches Ansprechen und der Verlauf …

Herausgeber:
Rudolf Puchner

2016 | Buch

Ambulant erworbene Pneumonie

Was, wann, warum – Dieses Buch bietet differenzierte Diagnostik und Therapie der ambulant erworbenen Pneumonie zur sofortigen sicheren Anwendung. Entsprechend der neuesten Studien und Leitlinien aller wichtigen Fachgesellschaften.

Herausgeber:
Santiago Ewig

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.

© Springer Medizin 

Bildnachweise